Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Endocare (ENDO) -- Ignore unavailable to you. Want to Upgrade?

To: _drichard1 who wrote (96)	10/27/2002 4:07:44 PM
From: jim heger	Respond to of 99

Yeah, that was ugly! I also don't attach any importance to the downgrades -those guys at a,h&h were calling for better than consensus $0.11 just a few weeks ago, so they were kept in the dark with everyone else. Sure , they're pissed off and citing "credibility". Mikus let expectations get way too far ahead of results . this co. may not be the rocket many (including me) thought it would be. the docs are a pretty conservative bunch, and not given to dumping a proven brachy treatment. I suppose the reimbursement issue will have a lot to do with the decisions to buy systems. The co. CFO said at the UBS presentation (you can still hear that webcast at the UBS site) that the news on higher pay outs would be announced in early Nov. Good news on that front could get the stock moving up . all things considered, i'd be kicking myself later if i didn't add here at the lowest price in years.